HOME >> MEDICINE >> NEWS
Mayo Clinic researchers report on effectiveness of treatments for hot flashes

; Sunday, May 15, 2005, 8 a.m. EDT

NCCTG Study Compares Venlafaxine and Progestational Agents in Reducing Hot Flashes

Mayo Clinic researchers will outline current data comparing the effectiveness of two medicines -- venlafaxine and a progestational agent -- in combating hot flashes.

Previous studies have shown that both venlafaxine and progestational agents substantially decrease hot flashes. This NCCTG trial demonstrated that a single dose of the progestational agent, medroxyprogesterone acetate (MPA), alleviated hot flashes more than did the daily use of the oral antidepressant venlafaxine (Effexor). Three to four weeks after treatment began, researchers observed that MPA was more effective than venlafaxine. This difference became even more striking after six weeks of treatment, says Mayo medical oncologist Charles Loprinzi, M.D., the NCCTG study's lead investigator.

"This improved hot flash benefit appeared to last for at least six months following a single MPA dose, with almost three times as many patients still reporting a 90 percent hot flash reduction following MPA versus patients receiving daily oral venlafaxine," says Dr. Loprinzi.

The findings reviewed in this presentation include data from 185 patients. Six weeks after treatment was started (compared to the baseline week), patients who received the single shot of MPA, versus those on venlafaxine, had greater reductions in median hot flash frequencies (85 percent vs. 52 percent reduction) and reductions in median hot flash scores (88 percent vs. 57 percent reduction).

Mayo researchers also noted that 24 percent of patients who received MPA reported no hot flashes after six weeks compared to 1 percent of venlafaxine patients. Patients on MPA also reported less trouble sleeping, less sleepiness, less constipation, less abnormal sweating and less hot flash distress than patients on venlafaxine.

The patients on venlafaxine had trends for less trou
'"/>


15-May-2005


Page: 1 2 3 4

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. New Mayo Clinic MRI technology enables noninvasive liver diagnoses
6. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
7. Elsevier launches the Clinics on ScienceDirect
8. Clinical guidelines for blood conservation during cardiac procedures developed
9. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
10. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 2007
11. Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... Director of its Sienna Plantation facility. , “We are pleased to announce Dr. ... Dr. Michael (Derek) Caraway, Area Medical Director of First Choice Emergency Room – North ...
(Date:8/16/2017)... ... ... Break Every Chain”: an inspirational story for those shackled by the chains of a broken ... Shivers, a writer and a woman of great faith and wisdom. She is a ... She was born and raised in Vero Beach, Florida and has dedicated her life and ...
(Date:8/15/2017)... Buffalo, NY (PRWEB) , ... August 15, 2017 , ... ... as maintenance treatment for multiple myeloma has been completed, with the team’s findings now ... Philip L. McCarthy, MD , Director of the Blood and Marrow Transplant Program at ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading dental ... the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The Tampa ... who has shown three consecutive years of growth. For this year’s award, Progressive Dental ...
(Date:8/15/2017)... ... 2017 , ... Dr. Timothy Davis is now administering two ... This information can be used to develop patient-specific treatment plans for periodontal disease ... tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® Labs, Inc., a subsidiary ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
Breaking Medicine Technology:
Cached News: